Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy : a Phase 3 Randomized Multicentric Open-label Study.

Chemotherapy induced peripheral neuropathy (CIPN) is a frequent and disabling complication of systemic chemotherapy, particularly with oxaliplatin or taxanes. The incidence of CIPN is variable but approximately 30-40% of patients treated with neurotoxic chemotherapy agents develop CIPN after long-term use of taxanes or oxaliplatin.
This CIPN is essentially a sensory peripheral neuropathy with pain manifested by unpleasant symptoms such as numbness, tingling, and less frequently shooting/burning pain. These symptoms spread proximally to affect both lower and upper extremities in a characteristic "stocking and glove" distribution.
Many symptoms of CIPN may resolve completely for some patients. However, CIPN is only partly reversible for most. In the worst instances, it does not appear to be reversible at all and can even increase over time.
CIPN is difficult to manage. Only duloxetine is recommended, based on the positive result of a randomized phase III double-blind placebo-controlled crossover trial. The use of duloxetine resulted in a greater reduction in pain and was effective in decreasing numbness and tingling in the feet. But, systemic antidepressants are often associated with toxicities and patients often refuse or abandon the treatment.
Capsaicin inhibits neural transmission in sensory axons and has been proven as effective on the intensity of pain for post-herpetic neuralgia and human immunodeficiency virus-associated neuropathy. Efficacy appears at one month and persists for at least 2 months.
Only a few studies focused on the efficacy of capsaicin 179 mg patch on the intensity of CIPN-induced pain. These non-randomized studies show that more than 50% of patients have a reduction in pain intensity of more than 30%.
Until now, no clinical trial has compared the efficacy of the capsaicin 179 mg patch with duloxetine.
Accordingly, this open-label phase 3, randomized, multicenter trial, will compare efficacy and safety of capsaicin patch with oral duloxetine on painful CIPN persisting more than 3 months after the end of the responsible chemotherapy.

开始日期2023-09-01

申办/合作机构

Institut de Cancerologie de L Ouest

[+1]

NCT05449132 / Recruiting临床3期

A Randomized, Double-blind, Placebo-controlled, Phase III Trial, to Evaluate the Efficacy and Safety of a Single Intra-articular Injection of RTX-GRT7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.

开始日期2022-08-26

申办/合作机构

Grünenthal GmbH

NCT05248386 / Recruiting临床3期

A Randomized, Double-blind, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Intra-articular Injections of RTX-GRT7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated injections of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.

开始日期2022-08-26

申办/合作机构

Grünenthal GmbH

0 项与 Grünenthal GmbH 相关的专利（医药）

登录后查看更多信息

141

项与 Grünenthal GmbH 相关的文献（医药）

2019-10-31·Experimental and Therapeutic Medicine

Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras

作者: Nachreiner, Inga ; Hussain, Ahmad Fawzi ; Wullner, Ulrich ; MacHuy, Nikolaus ; Meyer, Thomas F. ; Fischer, Rainer ; Gattenloehner, Stefan ; Meinhold-Heerlein, Ivo ; Barth, Stefan ; Tur, Mehmet Kemal

Breast cancer is the most common cancer in women worldwide. Despite recent developments in breast cancer detection and treatment, 1.38 million women each year are still affected. Breast cancer heterogeneity at the population and single-cell level, complexity and developing different metastases are setting several challenges to develop efficient breast cancer therapies. RNA interference (RNAi) represents an opportunity to silence gene expression and inhibit specifi pathways in cancer cells. In order to reap the full advantages of RNAi-based therapy, different pathways that sustain cancer cells growth have been targeted using specifi siRNAs. The present study investigated the ability of a set of cytotoxic siRNAs to inhibit growth of breast cancer cells. These siRNAs are targeting eukaryotic elongation factor 2 (EEF2), polo-like kinase 1 (PLK1), G protein-coupled receptor kinase 4 (GRK4) and sphingosine kinase interacting protein (SKIP5). To facilitate their targeted delivery, the human epidermal growth factor receptor-3 (HER3)-specifi aptamer A30 was used. The in vitro results described in this work indicate that combining the highly specific HER3 aptamer with cytotoxic siRNAs targeting (EEF2, PLK1, GRK4 and SKIP5) can inhibit its activity and ultimately suppress proliferation of HER3 pos. breast cancer cells.

2019-07-11·Journal of Medicinal Chemistry1区 · 医学

Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors

1区 · 医学

Article

作者: Alen, Jo ; Schade, Markus ; Wagener, Markus ; Christian, Frank ; Nordhoff, Sonja ; Merla, Beatrix ; Dunkern, Torsten R. ; Bahrenberg, Gregor ; Ratcliffe, Paul

Genome-wide-association studies in chronic low back pain patients identified sepiapterin reductase as a high interest target for developing new analgesics. Here we used ¹⁹F NMR fragment screening for the discovery of novel, ligand-efficient SPR inhibitors. We report the crystal structures of six chemically diverse inhibitors complexed with SPR, identifying relevant interactions and binding modes in the sepiapterin pocket. Exploration of our initial fragment screening hit led to double-digit nanomolar inhibitors of SPR with excellent ligand efficiency.

2019-03-01·European Journal of Pain (Oxford, United Kingdom)2区 · 医学

Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial

2区 · 医学

Article

作者: Eerdekens, Marie-Henriette ; Kapanadze, Sofia ; Koch, Erika Dietlind ; Kralidis, Georg ; Volkers, Gisela ; Ahmedzai, Sam Hjelmeland ; Meissner, Winfried

BACKGROUND:

Cancer-related pain is a growing health problem given the increasing life expectancy of cancer patients. Opioids are commonly used to treat cancer-related pain, but carry the risk of severe side effects, limiting their use. Cebranopadol is a first-in-class drug candidate, combining nociceptin/orphanin FQ peptide and opioid peptide receptor agonism. This trial examined the analgesic efficacy of cebranopadol compared with morphine prolonged release (PR) in patients with moderate-to-severe cancer-related pain.

METHODS:

This double-blind, parallel-group, multiple-dose trial was designed as noninferiority trial for efficacy of cebranopadol versus morphine PR. Planned with 524 patients, finally 126 patients were treated for up to 7 weeks (low accrual). The primary efficacy endpoint was the average amount of daily rescue medication intake (morphine immediate release) over the last 2 weeks of treatment.

RESULTS:

For the primary endpoint, noninferiority of cebranopadol with and superiority over morphine PR were demonstrated (Full Analysis Set: ∆[95%CI] = -7.48 mg [-12.05, -2.92]; Per Protocol Set: ∆[95%CI] = -4.67 mg [-9.25, -0.10]). The vast majority of patients (≥75%, either treatment) had clinically relevant pain reduction, and noninferiority on this secondary endpoint was not shown. Mostly used doses were ≤800 μg cebranopadol or ≤120 mg morphine PR daily. A total of 83.1% of patients on cebranopadol and 82.0% on morphine PR experienced treatment-emergent adverse events.

CONCLUSIONS:

Cebranopadol was effective, safe and well tolerated in the dose range tested (200-1,000 μg) in patients suffering from chronic moderate-to-severe cancer-related pain and was superior to morphine PR on the primary endpoint.

SIGNIFICANCE:

Cebranopadol presents a new approach to treat cancer pain. The drug candidate was easy to titrate, safe and well tolerated, and as effective as morphine PR in patients suffering from chronic moderate-to-severe cancer-related pain.

项与 Grünenthal GmbH 相关的新闻（医药）

2023-09-27

·新药前沿

【药物盐型和晶型专利十大典型案例】案例九：盐酸他喷他多晶型专利无效及行政纠纷案

盐酸他喷他多片/缓释片（商品名为Nucynta/Nucynta ER）是由杨森制药（Janssen Pharmaceuticals）和德国Gruenenthal GmbH公司联合开发的新型口服止痛药，其速释片和缓释片分别于2008年和2011年获美国FDA批准上市。专利号为200580021661.1，请日为2005年6月27日，优先权日为2004年6月28日，授权公告日为2011年6月15日，名称为“（-）-（1Ｒ,2Ｒ）-3-（3-二甲基氨基-1-乙基-2-甲基丙基）-苯酚盐酸盐的晶形”，专利权人为格吕伦塔尔公司的发明专利，保护了盐酸他喷他多晶型。请求人江苏恒瑞医药股份有限公司于2015年6月23日向国家知识产权局专利复审委员会提出无效宣告请求。经审查，专利复审委员会于2016年2月3日作出第28122号无效宣告请求审查决定，宣告本专利全部无效。格吕伦塔尔公司不服，连续提起行政诉讼。北京知识产权法院和最高人民法院都作出了驳回格吕伦塔尔公司的诉讼请求的判决。一、无效程序专利复审委员会于2016年2月3日作出第28122号无效宣告请求审查决定本专利权利要求1保护（-）-（1R,2R）-3-（3-二甲基氨基-1-乙基-2-甲基丙基）-苯酚盐酸盐的晶形A（即盐酸他喷他多晶型A），并通过X-射线图数据列表进行限定。权利要求2为该晶型制备方法。请求人提交的证据1实例25实际上公开了（-）-（1R,2R）-3-（3-二甲基氨基-1-乙基-2-甲基丙基）-苯酚盐酸盐的另一种晶型。国家知识产权局专利复审委员会举行口头审理，并于2016年2月3日作出无效决定，认为：在证据1的基础上结合证据3获得本专利权利要求1、2的技术方案对于本领域技术人员而言是显而易见的，因此，权利要求1、2相对于证据1和证据3的结合不具备创造性；在证据1的基础上结合证据3和证据4其他权利要求也不具备创造性。据此，宣告本发明专利权全部无效。二、司法程序二审诉讼当事人上诉人（原审原告）：格吕伦塔尔有限公司（GRUENENTHALGMBH）被上诉人（原审被告）：国家知识产权局原审第三人：江苏恒瑞医药股份有限公司1、一审回顾北京知识产权法院（2016）京73行初3201号行政判决（2019年1月30日）格吕伦塔尔公司认可被诉决定中有关权利要求1与证据1之间区别特征的认定，本专利权利要求1与证据1的区别仅在于晶型不同；而对基于该区别特征，被诉决定认定权利要求1实际解决的技术问题是提供一种具有不同晶型的可替代的盐酸他喷他多晶体，格吕伦塔尔公司持有异议，并主张权利要求1实际解决的技术问题是提供一种具有改善稳定性的盐酸他喷他多晶型。对此，原审法院认为，在确定发明实际解决的技术问题时，应当立足于相关区别特征在发明中所能达到的技术效果。从本专利说明书公开的内容来看，虽然其中记载了晶型A相对于晶型B在外界环境条件下更为稳定，但该内容仅为断言性的效果描述，对于具有明显实验属性的医药领域而言，除此之外还应有相关实验数据对该声称的效果予以佐证。在本专利说明书中，实施例16记载了从40℃到50℃，晶型A转变为晶型B，这表明在40℃到50℃的温度区间内，晶型A会转变为晶型B，即此时晶型B较晶型A更稳定。虽然实施例16中同时也记载了上述晶型转变的结果是可逆的，即在较低温度下，晶型B也会转变为晶型A，但该“较低温度”并无明确所指，无法使本领域技术人员进一步确定晶型A和晶型B在40℃以下的转变情况。而实施例5中的记载仅能表明在-40℃并存放72小时的情况下，晶型B会转变为晶型A，而对其他温度范围的晶型转变情况则未有涉及。显然，仅仅基于说明书中的以上内容，本领域技术人员无法确定在-40℃至40℃的温度区间内，晶型A与晶型B之间的相互转变情况，进而也无法确认晶型A在外界环境条件下（包括室温环境）具有如说明书所声称的更为稳定的效果。至于格吕伦塔尔公司提交的反证9，其中所涉及的是晶型A和晶型B在不同压力条件下的稳定性数据，然而一方面，上述内容系针对压力条件而非温度条件，且未记载在本专利的原说明书中，故不能采信并用以证明本专利说明书中所声称的效果；另一方面，根据反证9的内容，也无法确定其所使用的实验样品与本专利晶型A和晶型B之间的关系，故同样也不能证明本专利说明书所声称的更为稳定的效果。综上，鉴于说明书中所声称的晶型A具有更稳定的效果缺乏事实依据，无法确认本专利的晶型A相对于晶型B具有更好的稳定性，故格吕伦塔尔公司基于该效果而主张的权利要求1实际解决的技术问题亦不能成立。被诉决定对此认定正确，原审法院予以支持。从本专利权利要求1实际解决的技术问题出发，并结合证据3所公开的内容进行考虑，对于本领域技术人员而言，在研究制备固态有机药物时，最理想的情况是获得符合药物生产和使用需要的晶型，以此来提高药品的生物利用度和药效。在该固态有机药物还存在多种晶型时，鉴于各晶型在稳定性等方面的差异，本领域技术人员也有动机进行尝试和筛选，并从中选择出符合药物生产和使用需要的晶型，这通常可以借助常规技术手段得以实现。具体到本案情形，本专利权利要求1与证据1均涉及同一种化合物，即盐酸他喷他多。在证据1已经公开了盐酸他喷他多的一种晶体的基础上，本领域技术人员为了获得符合药物生产和使用需要的盐酸他喷他多晶型，完全可以在证据3所公开内容的教导下，将证据1的结晶条件予以具体化或做常规调整，并对所得到晶体的理化性能进行常规选择，进而得到本专利权利要求1的技术方案，这并不需要付出创造性劳动。另外需要指出的是，对于同一化合物存在多种晶型的情形，仅仅是研究制备出一种新的晶型，并不意味着相关技术方案已经可以满足创造性的要求，原因即在于本领域技术人员存在上述对已有晶型进行改进的动机，而且在技术实现上通常亦无障碍。此时，只有该新晶型相对于现有技术取得了预料不到的技术效果，才能佐证其具备创造性。但如前所述，并无证据表明本专利的晶型A相对于现有技术取得了任何预料不到的技术效果。因此，本专利权利要求1相对于证据1和证据3的结合，不具有突出的实质性特点和显著的进步，不具备专利法第二十二条第三款所规定的创造性。格吕伦塔尔公司的相关诉讼主张不能成立，原审法院不予支持。被诉决定对此认定正确，原审法院予以支持。原审法院判决：驳回格吕伦塔尔公司的诉讼请求。2、二审要点最高人民法院（2019）最高法知行终12号（2019年9月29日）格吕伦塔尔公司认可被诉决定对于区别特征的认定，但对被诉决定认定的权利要求1实际解决的技术问题有异议，认为本专利权利要求1实际解决的技术问题，是获得具有改善稳定性的盐酸他喷他多的新晶型。对此，本院认为，在确定权利要求1实际解决的技术问题时，应当立足于该区别特征在本专利中实际所能达到的技术效果，具体而言，需要判断本专利说明书公开的内容是否足以表明晶型A相比已知的晶型B具有更好的稳定性。基于说明书中公开的上述内容，本领域技术人员无法得出晶型A比晶型B具有更为稳定的效果的结论。此外，格吕伦塔尔公司关于新晶型A相对于已有的晶型B具有更好的稳定性的主张并没有得到本专利说明书公开内容的支持，更不可能具备预料不到的技术效果。因此，权利要求1相对于证据1和证据3的结合不具备创造性。格吕伦塔尔公司的相关上诉理由不能成立，二审法院不予支持。最终，格吕伦塔尔公司的上诉理由不能成立，对其上诉请求应予驳回。被诉决定对创造性的评价正确，程序合法；原审判决认定事实清楚，结论正确，应予维持。二审法院判决驳回上诉，维持原判。本文由「新药前沿」微信公众号根据公开资料整理编辑，欢迎个人转发至朋友圈。媒体或机构转载授权请在「新药前沿」微信公众号留言公众号名称，审核通过后开通白名单获取转载授权，转载请标识来源。免责声明：本文仅作信息交流之目的，非投资建议或者治疗方案推荐，「新药前沿」微信公众号不对任何主体因使用本文内容而导致的任何损失承担责任。限于作者水平和专业知识所限，如有谬误，欢迎指正！

专利无效

2023-08-02

·PRNewswire

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration

The Joint Venture Collaboration includes a portfolio of 13 brands across six therapeutic areas, with the majority of revenue resulting from pain management medicines The new enterprise will be branded as Grünenthal Meds. Grünenthal owns a 51 percent majority share and intends to acquire the remaining share at the beginning of 2026 AACHEN, Germany and TOKYO, Aug. 2, 2023 /PRNewswire/ -- Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the successful completion of a deal to enter into a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. All products will continue to be marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide. "Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain," said Gabriel Baertschi, Chief Executive Officer, Grünenthal. "The established medicines portfolio has a proud history of delivering life-changing value for patients. Today's announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality," said Jeremy Morgan, President, Kyowa Kirin International. Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026. About Grünenthal Meds As part of the Joint Venture Collaboration between Grünenthal GmbH and Kyowa Kirin Co., Ltd., a new enterprise has been created to market Kyowa Kirin International's established medicines portfolio, which comprises 13 brands across six therapeutic areas. This enterprise will be branded in all markets as Grünenthal Meds. The portfolio includes medicines that deliver life-changing value for hundreds of thousands of patients. The portfolio is available in seven major European markets through affiliates and in various additional territories worldwide through a network of partners. Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis. Visit to find out more. About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, we apply cutting-edge science, including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: . Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2022, Grünenthal employed around 4,400 people and achieved sales of € 1.7 bn. More information: and Grünenthal Report 2022/23 digital edition (grunenthal.com) SOURCE Grünenthal Group

引进/卖出

2023-06-27

·PRNewswire

Empowering the Future of Pain Relief Research: Recipients of the 2023 EFIC-Grünenthal Grant Announced

Three promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2023. The E-G-G funds innovative research projects to advance understanding of pain and improve the lives of people suffering from pain. BRUSSELS and AACHEN, Germany, June 27, 2023 /PRNewswire/ -- The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the three recipients of the EFIC-Grünenthal Grant (E-G-G). With a total value of €100,000, this biennial grant rewards innovative projects for human pain research and supports promising early-career researchers. Pain is a significant healthcare problem. More than 1.5 billion individuals suffer from chronic pain – almost one in five people worldwide.[1] Chronic Pain is one of the most common reasons for seeking medical help. It is also a frequent cause of people withdrawing from the labor market early and significantly contributing to disability retirement.2 It is associated with multiple conditions, and many patients struggle to find effective pain relief. The E-G-G aims to raise awareness of unmet needs in pain management. It supports young scientists, helping them explore novel ideas for pain research projects. The grant consists of up to €50,000 per project. The independent EFIC® Research Committee, a multidisciplinary team of experts in the pain field, selects the recipients. Selection criteria include originality of the project and the potential clinical impact. In addition to financial support, the winners also have the opportunity to network with pain research experts and communicate their research outcome to the scientific community at the biennial EFIC® Pain in Europe Congress. For nearly 20 years, the E-G-G grant has helped establish young scientists and clinicians as independent researchers in pain. "We received an impressive number of high-quality proposals for very innovative research. The process of reviewing each proposal was scientifically inspiring," says Prof. André Mouraux, chair of EFIC® Grants and Prizes Working Group and one of the 2008 E-G-G winners. "By investing in the next generation of researchers, we aim to ignite scientific breakthroughs that will shape the future of pain research," says Jan Adams, Chief Scientific Officer Grünenthal. "With this grant, we are not only providing financial support but also nurturing a spirit of innovation among young professionals, empowering them to pursue cutting-edge solutions that will revolutionize the way we understand and treat pain." 1. Treede RD, at al. Pain. 2015;156:1003-7. 2. Saastamoinen P, et al. Pain. 2012;153:526-31. The E-G-G winners 2023 E-G-G received 43 applications. In a two-step evaluation, seven selected reviewers and four members of the EFIC® Research Committee Working Group on Grants and Prizes selected three research projects for funding: Eleonora Maria Camerone, Italy Project title: Unveiling the Impact of Expectations on Chronic Pain: An Ecological Momentary Assessment Study Lieve Filbrich, Belgium Project title: Multisensory interactions in pain: uncovering their effect on the motor system Sampuna Chakrabarti, Germany Project title: Phenotype-driven neuro-proteomics to identify clinically relevant pain targets The winners will be officially recognised during the opening ceremony of the 13th Congress of the European Pain Federation EFIC® in Budapest, Hungary, from 20 to 22 September 2023. For further information, please visit About the European Pain Federation EFIC® Headquartered in Brussels, the European Pain Federation EFIC® is a multidisciplinary professional organisation in the field of pain research and pain management, consisting of the 38 chapters of the International Association for the Study of Pain (IASP®), the IASP® approved official National Pain Societies in each country. Established in 1993, the European Pain Federation EFIC® constituent chapters represent Pain Societies from 38 European countries and more than 20,000 physicians, basic researchers, nurses, physiotherapists, psychologists and other healthcare professionals across Europe, who are involved in pain management and pain research For more information: European Pain Federation - EFIC Follow @efic_org on Twitter About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focussing all of our activities and efforts on moving towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in around 100 countries. In 2022, Grünenthal employed around 4,400 people and reached a revenue of € 1.6 bn. More information: and Grünenthal Report 2022/23 digital edition (grunenthal.com) Follow us on: LinkedIn: Grunenthal Group Instagram: grunenthal Contacts: Sam Kynman Executive Director European Pain Federation EFIC® Rue de Londres 18 b3 B-1050 Brussels Email: [email protected] Fabia Kehren Head External Communication Grünenthal E-Mail: [email protected] Phone: +49 241 569 3269 SOURCE Grünenthal Group

管线布局

2023年10月04日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

醋酸氯地孕酮/炔雌醇 ( ER + PR )	怀孕更多	批准上市
辣椒碱 ( TRPV1 )	神经痛更多	批准上市
盐酸乐卡地平 ( Cav2.1 )	高血压更多	批准上市
奥美拉唑钠 ( Proton pump )	胃食管反流更多	批准上市
树胶脂毒素 ( TRPV1 )	关节炎疼痛更多	临床3期